Comparison of Efficacy and Safety of First-Line Chemoimmunotherapy in Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Figure 2

(a) The league table for OS. (b) The league table for PFS. (c) The rankogram for OS. (d) The rankogram for PFS. OS: overall survival; PFS: progression-free survival; tori: toripalimab; sinti: sintilimab; tisle: tislelizumab; camre: camrelizumab; pembro: pembrolizumab; nivo: nivolumab; chemo: chemotherapy.

(a)

(b)

(c)

(d)